Miruvor
Sign up
The short answer

What studies of stem cell therapy found

14papers on stem cell therapy
190people in 6 studies testing stem cell therapy alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 6 findings, all C.

6 outcomes rated · see each below

Preventing long COVID: D Little or no difference

Based on the strongest evidence, randomised trials and the randomised trial and the placebo trial (very low certainty): 7 of 9 findings are D.

9 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, stem cell therapy might help some people, but research can’t show it yet. For preventing long COVID, studies found little or no difference with stem cell therapy. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 14 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Stem cell therapy · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Stem cell therapy · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Breathlessness3 studies · 24 people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (24 in all); not all results were tested against chance; the studies disagree.

Studies with no comparison group3 studies · 24 people with results

Breathlessness improved.

The evidence is very uncertain about the effect of stem cell therapy on breathlessness in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (24 in all)
  • Not all results were tested against chance
  • The studies disagree
See the 3 studies
  1. Adipose-derived stromal vascular fraction cells to treat long-term pulmonary sequelae of coronavirus disease 2019: 12-month follow-up. (2024)

    People in the study
    5 in the study
    Dose
    40 million, single-dose
    Outcome
    Dyspnea
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)

    People in the study
    10 in the study · 9 with outcome data
    Dose
    2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14
    Outcome
    Respiration rates
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  3. Human umbilical cord-derived mesenchymal stem cell transplantation improves the long COVID. (2024)

    People in the study
    10 in the study
    Dose
    1.0 × 10 6 per kg weight, Days 0, 7, and 14
    Outcome
    CT severity score at Month 6 chest-high-resolution CT (HRCT)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 9 (few people) people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (9 in all).

Studies with no comparison group10 in the study · 9 with outcome data · treatment duration of 14 weeks · 2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14 (few people)

Fatigue improved.

The evidence is very uncertain about the effect of stem cell therapy on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (9 in all)
See the 1 study
  1. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)

    People in the study
    10 in the study · 9 with outcome data
    Dose
    2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14
    Outcome
    FAStotal Fatigue assessment scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 9 (few people) people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (9 in all).

Studies with no comparison group10 in the study · 9 with outcome data · treatment duration of 14 weeks · 2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14 (few people)

Low mood or anxiety improved.

The evidence is very uncertain about the effect of stem cell therapy on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (9 in all)
See the 1 study
  1. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)

    People in the study
    10 in the study · 9 with outcome data
    Dose
    2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14
    Outcome
    EP Short form questionnaire-36
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 9 (few people) people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (9 in all).

Studies with no comparison group10 in the study · 9 with outcome data · treatment duration of 14 weeks · 2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14 (few people)

Pain improved.

The evidence is very uncertain about the effect of stem cell therapy on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (9 in all)
See the 1 study
  1. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)

    People in the study
    10 in the study · 9 with outcome data
    Dose
    2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14
    Outcome
    P Short form questionnaire-36
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms2 studies · 34 people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (34 in all); not all results were tested against chance.

Studies with no comparison group2 studies · 34 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of stem cell therapy on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (34 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)

    People in the study
    10 in the study · 9 with outcome data
    Dose
    2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14
    Outcome
    VAStotal Visual analog scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Stem Cell Educator Therapy for Ex Vivo Immune Modulation of Peripheral Blood Mononuclear Cells in Patients with Long COVID. (2026)

    People in the study
    25 in the study
    Dose
    one treatment
    Outcome
    feeling refreshed, energized, and mentally clear
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning1 study · 9 (few people) people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (9 in all).

Studies with no comparison group10 in the study · 9 with outcome data · treatment duration of 14 weeks · 2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14 (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of stem cell therapy on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (9 in all)
See the 1 study
  1. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program. (2023)

    People in the study
    10 in the study · 9 with outcome data
    Dose
    2 × 108 live cells, 5 infusions at week 0, 2, 6, 10 and 14
    Outcome
    PF Short form questionnaire-36
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Preventing long COVID

Symptoms

Fatigue2 studies · 141 people received stem cell therapy Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (226 in all); the studies disagree; randomised trials found mixed results.

Randomised trials2 studies · 226 people with results

Studies disagree about fatigue.

Studies disagree about whether stem cell therapy helps fatigue. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (226 in all)
  • The studies disagree
See the 2 studies
  1. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. (2025)

    People in the study
    101 randomised · 100 started · 78 analysed
    Dose
    4 × 107 cells/dose, days 0, 3, and 6
    Outcome
    Fatigue or muscle weakness
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    chronic fatigue-like syndrome (CFs)
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 49 people received stem cell therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (78 in all).

The placebo trial101 randomised · 100 started · 78 analysed · three intravenous infusions on days 0, 3, and 6 · 4 × 107 cells/dose, days 0, 3, and 6

Low mood or anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of stem cell therapy on low mood or anxiety later, when given during acute COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (78 in all)
See the 1 study
  1. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. (2025)

    People in the study
    101 randomised · 100 started · 78 analysed
    Dose
    4 × 107 cells/dose, days 0, 3, and 6
    Outcome
    Emotional instability
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Breathlessness2 studies · 141 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 226 people in all; a small benefit can't be ruled out.

Randomised trials2 studies · 226 people with results

No clear difference in breathlessness.

The evidence is very uncertain about the effect of stem cell therapy on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 226 people in all; a small benefit can't be ruled out
See the 2 studies
  1. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. (2025)

    People in the study
    101 randomised · 100 started · 78 analysed
    Dose
    4 × 107 cells/dose, days 0, 3, and 6
    Outcome
    Breathlessness (mMRC grade ≥ 1) modified Medical Research Council scale (mMRC)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    incidence of LLN and modified mMRC dyspnea scores
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Pain2 studies · 141 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 226 people in all; a small benefit can't be ruled out.

Randomised trials2 studies · 226 people with results

No clear difference in pain.

The evidence is very uncertain about the effect of stem cell therapy on pain later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 226 people in all; a small benefit can't be ruled out
See the 2 studies
  1. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. (2025)

    People in the study
    101 randomised · 100 started · 78 analysed
    Dose
    4 × 107 cells/dose, days 0, 3, and 6
    Outcome
    Pain or discomfort
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    Chronic pain syndrome (CPs)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Smell and taste loss1 study · 92 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 148 people found no clear difference; a small benefit can't be ruled out.

The randomised trial210 randomised · 148 analysed · four-year follow-up (assessments conducted between March 16 and May 9, 2024) · three infusions

No clear difference in smell and taste loss.

The evidence is very uncertain about the effect of stem cell therapy on smell and taste loss later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 148 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    Neurosensorial syndrome (NSs)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Sleep1 study · 49 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 78 people found no clear difference; a small benefit can't be ruled out.

The placebo trial101 randomised · 100 started · 78 analysed · three intravenous infusions on days 0, 3, and 6 · 4 × 107 cells/dose, days 0, 3, and 6

No clear difference in sleep.

The evidence is very uncertain about the effect of stem cell therapy on sleep later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 78 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. (2025)

    People in the study
    101 randomised · 100 started · 78 analysed
    Dose
    4 × 107 cells/dose, days 0, 3, and 6
    Outcome
    Sleep difficulties
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning2 studies · 141 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; 226 people in all; a small benefit can't be ruled out.

Randomised trials2 studies · 226 people with results

No clear difference in daily functioning.

The evidence is very uncertain about the effect of stem cell therapy on daily functioning later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • 226 people in all; a small benefit can't be ruled out
See the 2 studies
  1. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial. (2025)

    People in the study
    101 randomised · 100 started · 78 analysed
    Dose
    4 × 107 cells/dose, days 0, 3, and 6
    Outcome
    Decreased usual activity
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    Physical Functioning 36-Item Short-Form Survey
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Overall symptoms1 study · 92 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 148 people found no clear difference; a small benefit can't be ruled out.

The randomised trial210 randomised · 148 analysed · four-year follow-up (assessments conducted between March 16 and May 9, 2024) · three infusions

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of stem cell therapy on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 148 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    General Health 36-Item Short-Form Survey
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Quality of life1 study · 92 people received stem cell therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 148 people found no clear difference; a small benefit can't be ruled out.

The randomised trial210 randomised · 148 analysed · four-year follow-up (assessments conducted between March 16 and May 9, 2024) · three infusions

No clear difference in quality of life.

The evidence is very uncertain about the effect of stem cell therapy on quality of life later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 148 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism. (2026)

    People in the study
    210 randomised · 148 analysed
    Dose
    three infusions
    Outcome
    Social Function 36-Item Short-Form Survey
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

Stopping because of side effects1 study
Side effects studies reported5 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset2 studies
Dizziness1 study
Fatigue1 study
Headache1 study
Worse symptoms or a flare1 study

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. Muscle mass gain and strength recovery after discharge of critical COVID-19 patients treated with mesenchymal stromal cell infusion: a randomized clinical trial.2026 · placebo trial · 16 randomised · 9 analysed
    Summary

    Published as a preprint, this single-centre, prospective, randomized, double-blind, placebo-controlled phase I/II trial asked whether intravenous umbilical-cord mesenchymal stromal cells (MSCs) affected body composition, function and sarcopenia after critical COVID-19. It enrolled 16 adults with SARS and mechanical ventilation in COVID-19 intensive care units; 10 received three doses of 5 × 105 UC-MSCs/kg every 48 hours and 6 received vehicle solution, both with conventional treatment. Assessments occurred at two and four months after infusion. Nine patients remained (MSC = 5; placebo = 4). Between two and four months, appendicular skeletal muscle mass (p = 0.004), appendicular skeletal muscle index (p = 0.004), phase angle (p = 0.014), left arm circumference (p = 0.033) and HGS (p = 0.009) showed better results for the MSCs group; TUG improved in both groups (p = 0.039). The authors also report no difference between groups in functional performance when comparing the same period, and no difference in sarcopenia diagnosis (p=0.81) or severe sarcopenia (p = 1.0). Deaths occurred in five MSC and one placebo participants; the authors state none were related to MSC infusion. In the final sample, 60% of the MSC group and 50% of the placebo group had secondary bacterial infections. The authors state limitations including the small sample size.

  2. Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.2025 · placebo trial · 101 randomised · 100 started · 78 analysed
    Summary

    This 36-month follow-up of a randomized, double-blind, placebo-controlled trial examined patients with severe COVID-19 in Wuhan. A total of 101 patients were enrolled and randomized; 65 received UC-MSC infusion (4 × 107 cells/dose on days 0, 3, and 6) plus standard treatment and 35 received placebo plus standard treatment. At the 36-month visit, 78 patients were assessed (49/64 in the MSC group and 29/34 in the placebo group), with a median follow-up of 1106.0 d. Outcomes included normal lung CT, TSS, 6-MWD, pulmonary function, SF-36 scores, Long COVID symptoms, new-onset comorbidities, tumor markers, and SARS-CoV-2 reinfection. Normal CT images were reported in 23/49 MSC patients and 10/29 placebo patients (OR = 1.68, 95% CI: 0.65–4.34). TSS was 1.0 vs 4.0 (difference −1.92, 95% CI: −4.98–1.15). Median 6-MWD was 430.00 m vs 420.00 m (difference −1.28, 95% CI: −28.58–26.02). The SF-36 GH score was 67.0 vs 50.0 (difference 12.86, 95% CI: 1.44–24.28, p = 0.0278); in the subgroup aged ≥65 years, GH was 70.0 vs 42.5 (difference 25.47, 95% CI: 9.44–41.49, p = 0.0031). Pulmonary function, other SF-36 aspects, and Long COVID symptoms showed no significant differences between groups. New-onset complications affected 22 patients (44.90%) in the MSC group and 21 patients (72.41%) in the placebo group. Reinfection occurred in 26/49 vs 19/28 (OR = 0.54, 95% CI: 0.20–1.41). 20 cases were lost to follow-up, and one patient in the MSC group withdrew consent prior to infusion; no new deaths occurred during this study.

  3. Mesenchymal stromal cell therapy for post-COVID-19 syndrome: associated impact and mechanism.2026 · randomised trial · 210 randomised · 148 analysed
    Summary

    This four-year follow-up pooled survivors of severe COVID-19 from two prospective cohorts established in Wuhan, China, in early 2020. Of 210 patients initially treated, 148 completed follow-up: 92 in the MSC group and 56 in the control group. The MSC group received three intravenous infusions of umbilical cord-derived MSC plus standard treatment; the control group received placebo or conventional therapy alone. At four years, overall PCS prevalence was 73.6% (109/148), and chronic fatigue-like syndrome (CFs) was the most common subtype at 50.7% (75/148). CFs incidence was lower in the MSC group than in the control group: 38/92 [41.3%] vs. 37/56 [66.1%], with an adjusted OR of 0.361 (95% CI 0.181–0.722; p=0.003). The SF-36 Role-Emotional domain differed between groups (difference 9.65, 95% CI 0.50–18.81; p=0.0389). The paper reports no significant differences in CT outcomes, functional capacity, or pulmonary function, and no significant associations for the other PCS subtypes. New-onset comorbidities were low and comparable; serum tumor marker testing showed no increased oncogenic risk. Death occurred in 1 participant in each group, and loss to follow-up was 24 in the MSC group and 36 in the control group. Withdrawals were not reported, and reasons for withdrawal were not reported. The authors state that the original trials were not statistically powered to detect PCS outcomes; therefore, causal inference cannot be definitively established.

  4. Stem Cell Educator Therapy for Ex Vivo Immune Modulation of Peripheral Blood Mononuclear Cells in Patients with Long COVID.2026 · no comparison group · 25 in the study
    Summary

    Twenty-five patients with long COVID (15 males and 10 females) received one treatment with Stem Cell Educator (SCE) therapy at an outpatient facility; peripheral blood mononuclear cells were analyzed at baseline and one month after treatment. There was no comparison group. Brain fog and fatigue resolved in 21 of 25 patients, and most participants reported feeling refreshed, energized, and mentally clear after therapy. The percentage of regulatory T cells increased from 5.76% ± 1.21% at baseline to 7.53% ± 3.17% at 1 month (P = 0.003). In 17/25 subjects with elevated IL-1β-positive cells, the percentage decreased from 8.43% ± 10.12% to 3.01% ± 6.07% (P = 0.0017). CXCL16-positive cells decreased from 63.98% ± 19.11% to 44.1% ± 24.52% (P = 0.03). CD4+CD45RO+CCR7− TEM cells decreased from 24.48% ± 10.13% to 16.65% ± 8.83% (P = 0.0003), and naïve CD4+CD45RO−CCR7+ T cells increased from 42.95% ± 12.63% to 49.42% ± 12.6% (P = 0.0026). Five subjects (5/25) experienced mild tingling and numbness during apheresis, which resolved, and one subject (1/25, 4.0%) experienced mild itching during the infusion. No significant adverse events were reported during the Gleukocell infusion. Withdrawals were not reported. The authors state the study was a small, open-label, single-site cohort without a concurrent control group.

  5. Human umbilical cord-derived mesenchymal stem cell transplantation improves the long COVID.2024 · no comparison group · 10 in the study
    Summary

    Ten long COVID patients discharged from hospital after COVID-19 treatment were enrolled in a prospective long-term follow-up. They received intravenous infusions of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) at 1.0 × 10^6 per kg weight on Days 0, 7, and 14, with 12-month follow-up. There was no control group; outcomes were compared before and after treatment in the same patients. Adverse events and clinical symptoms were recorded, with questionnaires, chest HRCT images and laboratory parameters. Nine patients completed the symptom evaluation; one was excluded for personal reasons. At Month 1, relief rates were decreased appetite 100%, sleep difficulties 89%, anxiety or depression 78%, memory issues 63%, and lack of concentration 45%. Quality-of-life score improved from 64.56 (6.27) to 80.00 (6.36) (p = 0.01). Median CT severity score decreased from 4.00 to 3.50 at Month 1, with six patients showing a decrease, and to 3.00 at Month 6, with seven showing a decrease; the baseline-to-Month 6 difference was reported as statistically significant. Two patients had normal CT images at Months 6 and 12, and two of 10 had lung lesions completely resolved. Infusion reactions were reported at 60%; six patients had fever (≤39°C) and five had transient worsening fatigue. No serious adverse events associated with UC-MSCs infusion were observed.

  6. Adipose-derived stromal vascular fraction cells to treat long-term pulmonary sequelae of coronavirus disease 2019: 12-month follow-up.2024 · no comparison group · 5 in the study
    Summary

    This prospective, open-label study enrolled five subjects with persistent cough and dyspnea after hospitalization for COVID-19 pneumonia at community health centers in Managua and Leon, Nicaragua. Subjects received a single dose of 40 million intravenous autologous AD SVF cells and were followed at 1, 3, 6 and 12 months. There was no control arm. The paper reports no significant adverse events related to the infusion out to 12 months; grade 1 liposuction-related postoperative pain, bruising and cutaneous sensitivity occurred in all patients and resolved in 3 weeks. Subject two developed a presumed bacterial pneumonia (grade 3) at 3 months, considered unrelated to SVF treatment, and subject five was lost to follow-up after 6 months. For symptoms, cough improved in 1 month for three subjects and dyspnea improved in 3 months for three subjects. Four subjects had improvements in pulmonary symptoms, pulmonary function tests and CT scans; FVC improved in four subjects by 1 month, FEV1 in three subjects at 12 months, DLCO in three subjects at 12 months, and TLC increased in the four subjects without subsequent pneumonia. CT abnormalities improved in subjects 1, 3, 4 and 5; subject 2 did not markedly improve at 12 months.

  7. Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.2023 · no comparison group · 10 in the study · 9 with outcome data
    Summary

    This expanded access program asked whether repeated intravenous infusions of autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) changed signs and symptoms in adults with post-COVID-19 syndrome. Ten eligible subjects were screened and enrolled (no screen failures), and all 10 received the investigational product at Hope Biosciences Research Foundation. Each received five infusions of 2 × 108 live HB-adMSCs at week 0, 2, 6, 10 and 14, over a treatment duration of 14 weeks, with follow-up at week 18 and end of study at week 40. There was no placebo comparator. Outcomes included total VAS and FAS scores and SF-36 scales. VAStotal median fell from 37.6 (IQR 33.1–44.3) to 4.90 (IQR 1.26–9.81), P=0.0039; FAStotal median fell from 33.0 (IQR 27.0–35.0) to 15.0 (IQR 13.0–19.0), P=0.0039. Respiration rates and oxygen saturation levels remained unchanged; both were within normal range at baseline. One subject was withdrawn due to lost to follow-up; EOS SF-36 analyses reported N=9. A total of 40 adverse events were recorded: 39 mild, one moderate, none severe; no serious adverse events and no deaths were reported. Headaches and influenza-like illness accounted for 30/40 AEs. Authors state limitations including small sample and no placebo comparator.

  8. Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2.2023 · case report · 1 in the study
    Summary

    This case report described one 25-year-old female with delayed and prolonged post-COVID parosmia and dysgeusia; the authors presented their treatment experience. There was no comparison group. Treatments included prednisone 0.5 mg/kg for 8 days, nasal irrigation with saline solution three times a day for 10 days plus Mupirocin for 10 days, Gabapentin 300 mg orally every 8 hours for 1 month, Escitalopram 5 mg daily, multivitamins, and olfactory rehabilitation. A transfusion of 50 million mesenchymal stem cells of endometrial origin showed no evidence of improvement even 8 weeks after it. The first COVID-19 vaccine dose was followed by an improvement of 25% of the parosmia and dysgeusia in the 7 days after application. After the second dose, an olfactory test found 40%, compared with 2 of 16 odors (12%) identified earlier. The report described mild improvement with prednisone, gabapentin, nasal irrigations and olfactory rehabilitation, greater after the second vaccine dose; improvement in depression but minimal improvement in parosmia and dysgeusia. Harms and withdrawals were not reported. Follow-up was 12 months after suffering the condition, when parosmia and dysgeusia still persisted.

  9. Sphenopalatine Ganglion Block for Postacute Sequelae SARS-CoV-2 Infection Headaches: A Case Report and Review of the Literature.2023 · case report · 1 in the study
    Summary

    This case report describes 1 patient in her 50s with postacute sequelae SARS-CoV-2 infection (PASC), or Long COVID, who was referred from the PASC clinic to the interventional pain clinic for persistent symptoms including headaches. There was no comparison group and no randomisation. The experimental treatment was a sphenopalatine ganglion block (SPGB) via an infrazygomatic approach, using a 2 mL solution consisting of 1mL of 10 mg/mL dexamethasone and 1 mL of 0.5% bupivacaine; the right side was treated first and then the left side. Background treatments included right and left stellate ganglion blocks, which temporarily relieved most symptoms for 2 weeks and completely resolved the anosmia and ageusia. After the right-sided SPGB, the patient reported more than an 80% improvement in headaches, blurry vision, and eye pain on the right, and significant improvement in sinus congestion, concentration, and short-term memory; the left-sided SPGB resulted in similar relief. The abstract reports an 80% improvement in symptoms after bilateral SPGB. To date, the patient still has significant relief with no refractory symptoms. Conservative therapies had minimal effects; LDN and mesenchymal stem cells gave short-term symptom relief; intravenous nicotinamide adenine dinucleotide therapy gave no alleviation in the last 2 months. No harms were described, and withdrawal from treatment was not reported. The patient was very pleased with the results of the injections into her nose. The authors state the single case is empirical until further case reports or series show similar benefits.

  10. Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.2026 · systematic review
    Summary

    This systematic review and meta-analysis searched PubMed, Embase, and CNKI for comparative studies in moderate, severe, or critical COVID-19 published up to September 2, 2024. It included 24 studies (13 RCTs and 11 non-randomized controlled trials; n = 1080) in the mortality meta-analysis; follow-up ranged from 1 week to 2 years. Patients received mesenchymal stromal cell (MSC) therapy plus standard care or control (standard care with or without placebo). Outcomes reported were mortality, adverse events (AEs), serious adverse events (SAEs), clinical recovery, hospitalization, chest imaging, inflammatory markers, and Long-COVID measures. The review found no significant differences in AEs or SAEs after MSC infusion; the pooled odds ratio was 1.04 (95% CI 0.63–1.71) for AEs and 0.89 (95% CI 0.57–1.40) for SAEs. Reported harms included transient facial flushing (n = 1), transient fever (n = 1), and transient hypoxemia (n = 1) in one study; SAEs were fewer in MSCs in one study (2/12 vs. 8/12, P =0.04); high blood pressure was 3.57% vs, 10.18% (P =0.048) in another. The authors concluded that MSC therapy may reduce mortality in patients with severe or critical COVID-19, with a favorable safety profile, while the effect in moderate illness remained inconclusive. They stated limitations including interrupted recruitment and incomplete follow-up reducing statistical power, inclusion of non-randomized trials with lower-quality evidence, and lack of standardized adverse event reporting.

  11. Risk factors and preventive interventions for post Covid-19 condition: systematic review2022 · systematic review
    Summary

    Why: to see whether treatments given during acute or early post-acute Covid-19 prevent post Covid-19 condition (symptoms ≥12 weeks after onset). Who: a systematic review of 31 studies; the searches were run on 28 July 2021 for the intervention question. Several preventive-intervention studies were retrospective controlled cohorts, and most were in hospitalized patients. What was given and compared: corticosteroids, antibiotics, hydroxychloroquine, therapeutic anticoagulation, zinc, intravenous immunoglobulin, oseltamivir, ganciclovir, human umbilical cord mesenchymal stem cells (12 vs 29), an ayurvedic formulation (30 vs 30), Chinese medicine (64 vs 32), telerehabilitation (14 vs 13), cognitive-motor therapy (42), photobiomodulation (5 vs 5), and screening with referrals. Found: certainty was very low throughout. Examples: with stem cells, adverse events were 0 and serious adverse events 0; with the ayurvedic formulation, fatigue was 1 (5%) vs 6 (26.1%); with photobiomodulation, respiratory symptoms were 0/5 (0%) vs 4/5 (80%); with telerehabilitation, adverse events were none reported; with Chinese medicine there was no significant difference in the improvement rates of symptoms, including fatigue, between the two groups (p > .05); antibiotic use was associated with salivary gland ectasia, aOR 8.34 (95% CI, 1.47–158.19).

  12. Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
    Summary

    This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.

  13. Stem Cell Therapy for Chronic Fatigue Syndrome: A Promising Approach2024 · lab study
    Summary

    Researchers conducted a qualitative descriptive case study series at a stem cell clinic to explore mesenchymal stem cell (MSC) therapy for people with chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME). Participants had previously been diagnosed with CFS and had undergone stem cell therapy; the report describes individual cases receiving mesenchymal stem cells derived from umbilical cord tissue. There was no comparison group, no randomisation, and no blinded assessment. The study reports participants' experiences and medical-record observations rather than a controlled trial. Fatigue levels were reported reduced after stem cell therapy, with varying degrees of improvement. Cognitive function improved, especially memory, concentration and mental clarity; joint and muscle pain decreased; and participants generally reported better quality of life and increased ability to perform daily tasks. Sleep quality showed some improvement, but sleep disturbances persisted to some extent for all participants. Fibromyalgia-related pain remained a challenge for a participant. Harms and withdrawals were not reported. The authors conclude that stem cell therapy presents a promising approach to managing CFS, while stating that further research is needed to establish standardized treatment protocols and assess long-term efficacy and safety, and noting challenges such as high costs, regulatory hurdles and the need for standardized protocols.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime